Huan Zhang

Ms. Huan Zhang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YYYunkai Yang
Yunkai Yang
HZHuan Zhang
Huan Zhang
SHShanshan Huang
Shanshan Huang
QCQian Chu
Qian Chu
Kristen rat sarcoma (KRAS) gene is one of the most common mutated oncogenes in solid tumors. Yet, KRAS inhibitors did not follow suit with the development of targeted therapy, for the structure of KRAS has been considered as being implausible to target for decades. Chemotherapy was the initial recommended therapy for KRAS-mutant cancer patients, which was then replaced by or combined with immunotherapy. KRAS G12C inhibitors became the most recent breakthrough in targeted therapy, with Sotorasib being approved by the Food and Drug Administration (FDA) based on its significant efficacy in multiple clinical studies. However, the subtypes of the KRAS mutations are complex, and the development of inhibitors targeting non-G12C subtypes is still at a relatively early stage. In addition, the monotherapy of KRAS inhibitors has accumulated possible resistance, acquiring the exploration of combination therapies or next-generation KRAS inhibitors. Thus, other non-target, conventional therapies have also been considered as being promising. Here in this review, we went through the characteristics of KRAS mutations in cancer patients, and the prognostic effect that it poses on different therapies and advanced therapeutic strategy, as well as cutting-edge research on the mechanisms of drug resistance, tumor development, and the immune microenvironment.

29 September 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
The CD47/SIRPα axis serves as a “do not eat me” signal, protecting normal cells from phagocytosis, but in the meantime, enabling immune evasion by tumor cells. Whereas substantial progress has been made in developing CD47 antagonists, achieving a balance between hematotoxicity and antitumor efficacy remains a critical challenge. In this study, we demonstrated that the bivalent anti-CD47 antibody, Hu5F9, caused severe anemia in both human CD47 knock-in mice lacking the CD47/SIRPα signal and human CD47/SIRPα double knock-in mice with complete signal, suggesting the CD47/SIRPα signal is not essential. Moreover, the single-arm CD47 antibody Hu5F9/gp120 exhibited only mild red blood cell (RBC) destruction in vitro and in vivo. These findings reveal that RBC toxicity induced by anti-CD47 antibodies is determined by the bivalency of the antibody rather than the CD47/SIRPα signal engagement. Based on this, we engineered TJH2201, a novel anti-CD47 antibody that avoids RBC agglutination while retaining high-affinity CD47 binding, robust signaling blockade, and enhanced pro-phagocytosis activity in vitro. In xenograft models with Raji and MV-4-11 cells, TJH2201 demonstrated potent antitumor activity without inducing body weight loss. These results suggest that TJH2201 is a promising CD47 antagonist that balances antitumor efficacy and hematologic safety, providing a new therapeutic approach for CD47-expressing malignancies.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S5: Microscopic images of in vitro RBC agglutination induced by Hu5F9/gp120 at concentrations from 0.046 µg/ml to 100 µg/ml. Scale bar = 100µm

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S8: In vitro human RBC agglutination assay of TJH2201 using samples from three different PBMC donors.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S3: Binding ability of Hu5F9/B2B, and their respective parent antibodies.

2 January 2026
Verified
Other
Open access
HZHuan Zhang
Huan Zhang
FHFufan He
Fufan He
LCLei Cao
Lei Cao
HNHaiqing Ni
Haiqing Ni
NLNinghuan Li
Ninghuan Li
QCQian Chu
Qian Chu
Supplementary Figure S12: In vivo PK profiles of TJH2201 in Balb/c mice.